Cytotoxicity of human recombinant arginase i (Co)-PEG5000 in the presence of supplemental L-citrulline is dependent on decreased argininosuccinate synthetase expression in human cells

Anti-Cancer Drugs

Volumn 23, Issue 1, 2012, Pages 51-64

  Agrawal, Vaidehi ^a   Woo, Jung Hee ^a   Mauldin, Jeremy P ^a   Jo, Chanhee ^a   Stone, Everett M ^b   Georgiou, George ^b   Frankel, Arthur E ^a  

^a SCOTT AND WHITE MEMORIAL HOSPITAL   (United States)

^b The University of Texas at Austin   (United States)

Author keywords

acute myeloid leukemia; arginase; arginine depletion argininosuccinate synthetase; cancer

Indexed keywords

ARGININOSUCCINATE SYNTHASE; CITRULLINE; CYTOTOXIC AGENT; RECOMBINANT ARGINASE I POLYETHYLENE GLYCOL 5000; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EXPOSURE; DRUG POTENCY; DRUG SELECTIVITY; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IN VITRO STUDY; LIVER CELL CARCINOMA; LUNG ADENOCARCINOMA; MELANOMA; MESOTHELIOMA; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROTEIN EXPRESSION; PROTEIN SYNTHESIS INHIBITION; TISSUE CULTURE;

ANTINEOPLASTIC AGENTS; ARGINASE; ARGININE; ARGININOSUCCINATE SYNTHASE; CELL LINE, TUMOR; CELL PROLIFERATION; CITRULLINE; CULTURE MEDIA; DRUG SCREENING ASSAYS, ANTITUMOR; EPITHELIAL CELLS; HUMANS; MALE; ORNITHINE CARBAMOYLTRANSFERASE; POLYETHYLENE GLYCOLS; PROTEIN SYNTHESIS INHIBITORS; RECOMBINANT PROTEINS;

EID: 82555197938     PISSN: 09594973     EISSN: 14735741     Source Type: Journal    
DOI: 10.1097/CAD.0b013e32834ae42b     Document Type: Article

References (50)

1. Tennant DA, Duran RV, Gottlieb E. Targeting metabolic transformation for cancer therapy. Nature Reviews Cancer 2010; 10:267-277.
2. Gilroy E. The influence of arginine upon the growth rate of a transplantable tumour in the mouse. Biochem 1930; 24:589-595.
3. Yeatman TJ, Risley GL, Brunson ME. Depletion of dietary arginine inhibits growth of metastatic tumor. Arch Surg 1991; 126:1376-1381.
4. Kenny GE, Pollock ME. Mammalian cell cultures contaminated with pleuropneumonia-like organisms: I. Effect of pleuropneumonia-like organisms on growth of established cell strains. J Infect Dis 1963; 112: 7-16.
5. Miyazaki K, Takaku H, Umeda M, Fujita T, Huand WD, Kimura T, et al. Potent growth inhibition of human tumor cells in culture by arginine deiminase purified from a culture medium of a mycoplasma-infected cell line. Cancer Res 1990; 50:4522-4527. (Pubitemid 20230386)
6. Sugimura K, Ohno T, Fukuda S,Wada Y, Kumura T, Azuma I. Tumor growth inhibitory activity of a lymphocyte blastogenesis inhibitory factor. Cancer Res 1990; 50:345-349. (Pubitemid 20041239)
7. Dillon BJ, Prieto VG, Curley SA, Ensor CM, Holtsberg FW, Bomalaski JS, et al. Incidence and distribution of argininosuccinate synthetase deficiency in human cancers. Cancer 2004; 100:826-833.
8. Shen LJ, Lin WC, Beloussow K, Shen WC. Resistance to the antiproliferative activity of recombinant arginine deiminase in cell culture correlates with the endogenous enzyme, arginonsuccinate synthetase. Cancer Letters 2003; 191:165-170. (Pubitemid 36255601)
9. Wheatley DN, Kilfeather R, Stitt A, Campbell E. Integrity and stability of the citrulline-arginine pathway in normal and tumor cell lines. Cancer Letters 2005; 227:141.
10. Savaraj N, You M, Wangpaichitr M, Kuo MT, Feun LG. Arginine deprivation, autophagy, apoptosis (AAA) for the treatment of melanoma. Curr Mol Med 2010; 10:405-412.
11. Szlosarek PW, Klabatsa A, Pallaska A, Sheaff M, Smith P, Crook T, et al. In-vivo loss of expression of argininosuccinate synthetase in malignant pleural mesothelioma is a biomarker for susceptibility to arginine depletion. Clin Cancer Res 2006; 12:7126-7131. (Pubitemid 44974513)
12. Bowles TL, Kim R, Galante J, Parson CM, Virudachalam S, Kung HJ, et al. Pancreatic cancer cell lines deficient in argininosuccinate synthetase are sensitive to arginine deprivation by arginine deiminase. Int J Cancer 2008; 123:1950-1955.
13. Kim RH, Coates JM, Bowles TL, McNerney GP, Sutcliffe J, Jung JU, et al. Arginine deiminase as a novel therapy for prostate cancer induces autophagy and caspase-independent apoptosis. Cancer Res 2009; 69:700-708.
14. Bomalaski JS, Ivett JL, Vegarra M, Holtsberg FW, Ensor CM, Clark MA. Comparative toxicity of arginine deiminase formulated with poly(ethylene glycol) 5000 or 20,000 and the effects of arginine. Preclinical 2003; 1:284-293.
15. Tsui SM, Lam WM, Lam TL, Chong HC, So PK, Kwok SW, et al. Pegylated derivatives of recombinant human arginase (rhArg I) for sustained in vivo activity in cancer therapy: preparation, characterization and analysis of their pharmacodynamics in vivo and in vitro and action upon hepatocellular carcinoma cell (HCC). Cancer Cell International 2009; 9:9.
16. Yang TS, Lu SN, Chao Y, Sheen IS, Lin CC,Wang TE, et al. A randomized phase II study of pegylated arginine deiminase (ADI-PEG20) in Asian advanced hepatocellular carcinoma patients. Br J Cancer 2010; 103: 954-960.
17. Auron A, Brophy PD. Hyperammonemia in review: pathophysiology, diagnosis, and treatment. Pediatric Nephrology 2011; E-pub ahead of print.
18. Healy P, Dennis J, Rawlinson R. Prenatal diagnosis of bovine citrullinaemia. Cancer Letters 1993; 277:91-100.
19. Lam TL, Wong GK, Chong HC, Cheng PN, Choi SC, Chow TL, et al. Recombinant human arginase inhibits proliferation of human hepatocellular carcinoma by inducing cell cycle arrest. Cancer Letters 2009; 277: 91-100.
20. Cheng PNM, Lam TL, Lam WM, Tsui SM, Cheng AW, Lo WH, et al. Pegylated recombinant human arginase (rhArg-peg5,000mw) inhibits the in-vitro and in-vivo proliferation of human hepatocellular carcinoma through arginine depletion. Cancer Res 2007; 67:309-317. (Pubitemid 46142789)
21. MacLeod CL, Finley KD, Kakuda DK. y+-type cationic amino acid transport: expression and regulation of the mCAT genes. J Exp Biol 1994; 196: 109-121.
22. Stone EM, Glazer E, Chantranupong L, Cherukuri P, Breece RM, Tierney DL, et al. Replacing Mn2+ with Co2+ in human arginase I enhances cytotoxicity towards L-arginine auxotrophic cancer cell lines. ACS Chem Biol 2010; 5:333-342.
23. Stone EM, Chantranupong L, Georgiou G. The second-shell metal ligands of human arginase affect coordination of the nucleophile and substrate. Biochemistry 2010; 49:10582-10588.
24. Ascierto PA, Scala S, Castello G, Daponte A, Simeone E, Ottaiano A, et al. Pegylated arginine deiminase treatment of patients with metastatic melanoma: results from phase I and II studies. J Clin Oncol 2005; 23: 7660-7668. (Pubitemid 46291831)
25. Glazer ES, Piccirillo M, Albino V, Di Giacomo R, Palaia R, Mastro AA, et al. Phase II study of pegylated arginine deiminase for nonresectable and metastatic hepatocellular carcinoma. J Clin Oncol 2010; 28: 2220-22 26.
26. Bobak YP, Vynnytska BO, Kurlishchuk YV, Sibirny AA, Stasyk OV. Cancer cell sensitivity to arginine deprivation in vitro is not determined by endogenous levels of arginine metabolic enzymes. Cell Biol Int 2010; 34:1085-1089.
27. Tam IK, Gajra B. Plasma and urine amino acid profiles in a healthy adult population of Singapore. Ann Acad Med Singapore 2006; 35: 468-475. (Pubitemid 44450151)
28. Hernandez CP, Morrow K, Lopez-Barcons LA, Zabaleta J. Pegylated arginase. I A potential therapeutic approach in T-ALL. Blood 2010; 115:5214-5221.
29. Alfano RW, Leppla SH, Liu S, Bugge TH, Ortiz JM, Lairmore TC, et al. Inhibition of tumor angiogenesis by the matrix metalloproteinase-activated anthrax lethal toxin in an orthotopic model of anaplastic thyroid carcinoma. Mol Cancer Ther 2010; 9:190-201.
30. Gong H, Zölzer F, von Recklinghausen G, Havers W, Schweigerer L. Arginine deiminase inhibits proliferation of human leukemia cells more potently than asparaginase by inducing cell cycle arrest and apoptosis. Leukemia 2000; 14:826-829. (Pubitemid 30235059)
31. Gong H, Zölzer F, von Recklinghausen G, Rossler J, Breit S, Havers W, et al. Arginine deiminase inhibits cell proliferation by arresting cell cycle and inducing apoptosis. Biochem Biophys Res Commun 1999; 261: 10-14. (Pubitemid 29371610)
32. Rodriguez PC, Quiceno DG, Ochoa AC. L-arginine availability regulates T-lymphocyte cell-cycle progression. Blood 2007; 109:1568-1573. (Pubitemid 46239590)
33. Fafournoux P, Bruhat A, Jousse C. Amino acid regulation of gene expression. Biochem J 2000; 251:1-12.
34. Suto H, Yasuda H, Isobe Y, Sasaki M, Imai H, Tsutsui M, et al. Suppression of eIF4E expression by L-asparaginase. Acta Haematologica 2010; 123: 215-219.
35. Glazer ES, Kaluarachchi WD, Massey KL, Zhu C, Curley SA. Bioengineered arginase I increases caspase-3 expression of hepatocellular and pancreatic carcinoma cells despite induction of argininosuccinate synthetase-1. Surgery 2010; 148:310-318.
36. Selamnia M, Robert V, Mayeur C, Delpal S, Blachier F. De novo synthesis of arginine and ornithine from citrulline in human colon carcinoma cells: metabolic fate of L-ornithine. Biochem Biophys Acta 1998; 1425: 93-102. (Pubitemid 28479716)
37. Wek RC, Jiang HY, Anthony TG. Coping with stress: eIF2 kinases and translational control. Biochem Soc Trans 2006; 34:7-11. (Pubitemid 43235522)
38. Silverman LB, Supko JG, Stevenson KE, Woodward C, Vrooman LM, Neuberg DS, et al. Intravenous PEG-asparaginase during remission induction in children and adolescents with newly diagnosed acute lymphoblastic leukemia. Blood 2010; 115:1351-1353.
39. Jaccard A, Gachard N, Marin B, Surarez F, Tilly H, Morschhauser F, et al. Efficacy of L-asparaginase with methotrexate and dexamethasone (AspaMetDex regimen) in patients with refractory or relapsing extranodal NK/T-cell lymphoma, a phase II study. Blood 2010; 117: 1834-1839.
40. Tomita N, Fujita H, Koharazawa H, Maruta A, Kodama F, Yamamoto T, et al. Complete remission achieved by L-asparaginase vincristine, prednisolone (LVP) therapy in secondary leukemia (M5a type) with an MLL gene rearrangement. Jpn J Cancer Res 1997; 38:135-141.
41. Ensor CM, Holtsberg FW, Bomalaski JS, Clark MA. Pegylated arginine deiminase (ADI-SS PEG20,000 mw) inhibits human melanomas and hepatocellular carcinomas in vitro and in vivo. Cancer Res 2007; 62: 5443-5450.
42. Feun LG, You M,Wu C, Kuo MT,Waugpaichitr M, Spector S, et al. Arginine deprivation as a targeted therapy for cancer. Curr Pharm Design 2008; 14:1049-1057. (Pubitemid 351982554)
43. Manca A, Sini M, Izzo F, Ascierto PA, Tatangelo F, Botti G, et al. Induction of argininosuccinate synthetase (ASS) expression affects the antiproliferative activity of arginine deiminase (ADI) in melanoma cells. Oncology Rep 2011; 25:1495-1502.
44. Tsai WB, Aiba I, Lee SY, Feun L, Savaraj N, Kuo MT. Resistance to arginine deiminase in melanoma cells is associated with induced argininosuccinate synthetase expression involving c-Myc/HIF-1a/SP4. Mol Cancer Ther 2009; 8:3223-3233.
45. Kuo MT, Savaraj N, Feun LG. Targeted cellular metabolism for cancer chemotherapy with recombinant arginine-degrading enzymes. Oncotarget 2010; 1:246-251.
46. Savaraj N, Wu C, Kuo M, You M, Wangpaichitr M, Robles C, et al. The relationship of arginine deprivation, argininosuccinate synthetase and cell death in melanoma. Drug Target Insights 2007; 2: 119-128.
47. Wek RC, Cavener DR. Translational control and the unfolded protein response. Antioxid Redox Signaling 2007; 9: 2357-2371. (Pubitemid 350064140)
48. Feun LG, You M,Wu C,Wangpaichitr M, Kuo MT, Marini A, et al. Final results of phase II trial of pegylated arginine deiminase (ADI-PEG20) in metastatic melanoma (MM). J Clin Oncol 2010; 28:8528.
49. You M, Savaraj N, Wangpaichitr M, Wu C, Kuo MT, Varona-Santos J, et al. The combination of ADI-PEG20 and TRAIL effectively increased cell death in melanoma cell lines. Biochem Biophys Res Commun 2010; 394: 760-766.
50. Yau CC, Chan P, Pang R, Chan W, Cheng PN, Poon R. A phase I study of recombinant human arginase (rhArgI) for patients with advanced hepatocellular carcinoma. J Clin Oncol 2010; 28:3503.